---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-085653"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T17:56:28.133514+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# KalVista Pharmaceuticals enters lease for HQ and lab in Framingham; aggregate rent ~$11.2M

## Summary
- Lease for 32,110 sq ft at 200 Crossing Blvd, Framingham, MA, as corporate HQ and lab space.
- Commencement on or about April 30, 2025; lease expires December 31, 2034.
- Aggregate base rent payments of approximately $11.2 million over the term.
- Security deposit of ~$652,800 in the form of a letter of credit.
- Company to pay pro rata share of operating expenses and certain taxes.

## SEC filing metadata
- accession: 0000950170-24-085653
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/0000950170-24-085653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024085653/kalv-20240722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-085653
- JSON: https://secwatch.observer/filing/0000950170-24-085653.json
- Plain text: https://secwatch.observer/filing/0000950170-24-085653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.